Month: February 2024

Global Magnesium Market to Surpass USD 7.45 billion by 2031 Driven by Increasing Demand for Aluminum and Steel Alloy

Written by Customer Service on February 20, 2024. Posted in Mergers And Acquisitions.

SkyQuest projects that the global magnesium market will attain a value of USD 7.45 billion by 2031, with a CAGR of 9.3% during the forecast period (2024-2031). Increasing demand for materials for various applications such as die-casting, and aluminum alloys for industrial purposes drives the growth of global magnesium market. Magnesium’s electromagnetic properties, heat capacity, and reinforcing nature are suitable for such industrial applications. Magnesium is an increasingly useful metallurgical element in the automotive industry, as well as in the aerospace industry, in the upcoming research and development projects for electric vehicles. Magnesium production has reached around 950,000 metric tons by 2021 due to and for growing demand. Westford,USA, Feb. 20, 2024 (GLOBE NEWSWIRE) — Magnesium metal can store energy and...

DIH Reports First Half Fiscal 2024 Financial Results

Written by Customer Service on February 20, 2024. Posted in Earnings Releases And Operating Results.

NORWELL, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) — DIH Holding US, Inc. (“DIH”)(NASDAQ:DHAI), a leading global robotics and virtual reality (“VR”) technology provider in the rehabilitation and human performance industry, today reported financial results for the six months ended September 30, 2023. Recent HighlightsRevenue of $27.3 million for the 6 months end September 30, 2023, representing growth of 57.7% over the prior year period Revenue from device sales in the 6 months end September 30, 2023 increased by 73.9% Publicly listed on Nasdaq Global Markets following completion of the business combination with Aurora Technology Acquisition Corp (ATAK) on February 7, 2024 Introduction of the Armeo®Spring Pro to the upper extremity device portfolio“We are very pleased with the Company’s performance in the first half...

LGI Homes, Inc. Reports Fourth Quarter and Full Year 2023 Results and Issues Guidance for 2024

Written by Customer Service on February 20, 2024. Posted in Earnings Releases And Operating Results.

THE WOODLANDS, Texas, Feb. 20, 2024 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH) today announced financial results for the fourth quarter and year ended December 31, 2023. “We delivered a strong performance in the fourth quarter and successfully achieved all of our guidance targets for 2023,” said Eric Lipar, Chairman and Chief Executive Officer of LGI Homes. “At the same time, we laid the foundation for profitable growth for years to come. “Our strong execution in the fourth quarter resulted in full year closings of 6,729 homes and revenue of $2.4 billion. We believe these results make us one of just a few homebuilders to have delivered growth in both of these metrics in 2023. We made considerable progress in growing our community count and ended the year with 117 active communities, an increase of 18.2%. Our full year gross...

Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Written by Customer Service on February 20, 2024. Posted in Earnings Releases And Operating Results.

Total 4Q and full year 2023 net product revenue of $71.5 million and $204.9 million, respectively, representing year-over-year growth of 193% and 309% Auvelity 4Q and full year 2023 net product sales of $49.0 million and $130.1 million, respectively, during the first full year of launch Sunosi 4Q and full year 2023 net product revenue of $22.5 million and $74.8 million, respectively, representing 17% and 67% year-over-year growth NDA submission for AXS-14 in fibromyalgia and NDA resubmission for AXS-07 in migraine, both anticipated in 1H 2024 Topline results of the SYMPHONY Phase 3 trial in narcolepsy anticipated in 1Q 2024 Topline results of the ADVANCE-2 Phase 3 trial in Alzheimer’s disease agitation and the FOCUS Phase 3 trial in ADHD expected in 2H 2024 Initiation of Phase 3 trials of solriamfetol in major depressive disorder, binge...

California’s Foothill Transit to add 12 Enviro500EV double deck zero-emission buses from NFI subsidiary Alexander Dennis

Written by Customer Service on February 20, 2024. Posted in Public Companies.

LARBERT, United Kingdom, Feb. 20, 2024 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) NFI Group Inc. (NFI or the Company), a leading independent bus and coach manufacturer and a leader in electric mass mobility solutions, subsidiary Alexander Dennis Limited (Alexander Dennis) today announced it has been awarded a contract to build 12 new battery-electric Enviro500EV double deck buses for California customer Foothill Transit. Foothill Transit is a leading public transit agency serving 22 cities in the San Gabriel and Pomona valleys in eastern Los Angeles Country, California. Committed to innovation and sustainability, Foothill Transit strives to provide reliable and eco-friendly transportation solutions for the communities it serves. Its flagship Silver Streak route to downtown Los Angeles will be further upgraded in 2026...

Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results

Written by Customer Service on February 20, 2024. Posted in Public Companies.

SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2023 financial results after the close of U.S. financial markets on Tuesday, February 27, 2024. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (888) 886-7786 for domestic callers and (416) 764-8658 for international callers. A live webcast and archived replay of the event will be available here or online from the investor relations section of the company website at www.kuraoncology.com. About Kura Oncology Kura...

Dragonfly Energy Expands Market Share with RV Giant Forest River

Written by Customer Service on February 20, 2024. Posted in Public Companies.

The RV Manufacturer’s New OGV Luxury Coach Division to Include Dragonfly Energy Lithium Batteries Standard on All UnitsForest River OGV and Dragonfly Energy’s Battle Born Batteries at the Florida RV SupershowForest River OGV and Dragonfly Energy’s Battle Born Batteries at the Florida RV SupershowDragonfly Energy Battle Born Batteries now come as factory installed standard equipment on all new OGV Luxury Coach units. OGV Luxury Coach is the third Forest River, Inc. brand to include Battle Born Batteries as standard or optional equipment for customers. This is the latest partnership in an ever-growing list of RV brands to implement Dragonfly Energy lithium batteries as standard equipment.RENO, Nev., Feb. 20, 2024 (GLOBE NEWSWIRE) — Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) (“Dragonfly Energy” or the...

Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD

Written by Customer Service on February 20, 2024. Posted in Public Companies.

COPENHAGEN, Denmark, Feb. 20, 2024 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces the successful completion of the initial phases of its vaccine collaboration with MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA). The vaccine development project combines both organizations’ unique capabilities and know-how. Evaxion’s Chief Executive Officer Christian Kanstrup expresses enthusiasm, “In September last year, we announced a collaboration with a leading pharma company, and today we are proud to present that this collaborator is MSD. Further, we are excited about the successful conclusion of the vaccine target discovery and design phases...

Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis

Written by Customer Service on February 20, 2024. Posted in Public Companies.

ORALTO Phase 3 trial focused on desired initial target indication of early oral step-down treatment of invasive aspergillosis infections in adults who have limited or no treatment options Non-inferiority trial will enroll approximately 216 patients with primary endpoint of all-cause mortality at day 42 Key secondary endpoint includes superiority of oral step-down treatment with MAT2203 vs. AmBisome® (liposomal amphotericin B) for treatment-related toxicities leading to changes in treatment BEDMINSTER, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) — Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces alignment with the U.S. Food and Drug Administration (FDA) on the design of a single Phase...

Venus Concept to Release Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024

Written by Customer Service on February 20, 2024. Posted in Public Companies.

TORONTO, Feb. 20, 2024 (GLOBE NEWSWIRE) — Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that fourth quarter and fiscal year 2023 financial results will be released before the market opens on Monday, April 1, 2024. Management will host a conference call at 8:00 a.m. Eastern Time on April 1, 2024 to discuss the results of the quarter and the year with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13744647. A live webcast of the call will also be provided on the investor relations section of the Company’s website at ir.venusconcept.com. For those unable to participate, a replay of the call will be available for two weeks at: 877-660-6853...

Month: February 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals